Peak Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PKBO research report →
About the company
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges.
- CEO
- Hoyoung Huh
- IPO
- 2021
- Employees
- 6
- HQ
- Palo Alto, CA, US
Price Chart
- Market Cap
- $520.31K
- P/E
- -3.13
- P/S
- 0.00
- P/B
- 0.35
- EV/EBITDA
- -901.78
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -11.16%
- ROIC
- -10.28%
- Revenue
- $0 · -100.00%
- Net Income
- $-1,676.22 · -33.11%
- EPS
- $-0.02 · -44944.94%
- Op Income
- $-1,673.558
- FCF YoY
- 0.00%
- 52W High
- $0.02
- 52W Low
- $0.02
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.78
- Avg Volume
- 0
Get TickerSpark's AI analysis on PKBO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 7, 24 | SBI INVESTMENT KOREA CO., LTD. | other | 83,800 |
| Nov 14, 24 | SBI INVESTMENT KOREA CO., LTD. | sell | 3,621,489 |
| Nov 14, 24 | Patel Sandip I | other | 763,316 |
| Nov 14, 24 | Patel Sandip I | sell | 400,000 |
| Nov 14, 24 | Patel Sandip I | sell | 47,364 |
| Nov 14, 24 | Patel Sandip I | other | 0 |
| Nov 14, 24 | Neal James R | other | 37,850 |
| Nov 14, 24 | Neal James R | other | 0 |
| Nov 14, 24 | Neal James R | sell | 37,850 |
| Nov 14, 24 | Neal James R | sell | 33,340 |
Our PKBO coverage
Recent articles, reports, and earnings notes.
No research on PKBO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PKBO report →Similar companies
Peers in the same neighborhood.